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The development of topical microbicides is a valid approach to protect the genital mucosa from sexually
transmitted infections that cannot be contained with effective vaccination, like HSV and HIV infections. A
suitable target of microbicides is the interaction between viral proteins and cell surface heparan sulfate
proteoglycans (HSPGs). AGMA1 is a prevailingly cationic agmatine-containing polyamidoamine polymer
previously shown to inhibit HSPGs dependent viruses, including HSV-1, HSV-2, and HPV-16. The aim of
this study was to elucidate the mechanism of action of AGMA1 against HSV infection and assess its
antiviral efﬁcacy and biocompatibility in preclinical models. The results show AGMA1 to be a non-toxic
inhibitor of HSV infectivity in cell cultures and human cervicovaginal histocultures. Moreover, it
signiﬁcantly reduced the burden of infection of HSV-2 genital infection in mice. The investigation of the
mechanism of action revealed that AGMA1 reduces cells susceptibility to virus infection by binding to
cell surface HSPGs thereby preventing HSV attachment. This study indicates that AGMA1 is a promising
candidate for the development of a topical microbicide to prevent sexually transmitted HSV infections.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Herpes Simplex Viruses type 1 and 2 (HSV-1 and HSV-2) are
closely related pathogens belonging to the Herpesviridae family of
DNA viruses that cause a wide variety of clinical manifestations in
humans: HSV-1 is more frequently associated with oral and labial
lesions, whereas HSV-2 typically infects genital mucosa. However,
both viruses can infect both oral and genital regions, and the inci-
dence of genital infections, particularly those caused by HSV-1, are
on the increase [1]. Following primary infection, HSVs establishd Biological Sciences, Univer-
, Turino, Italy.life-long latency in the neurons of the sensory ganglia proximal to
the site of entry. Then, triggered by several viral and host factors,
they periodically reactivate, descend into the primary site of
infection, and replicate; leading to asymptomatic or symptomatic
viral shedding [2]. Occasionally, HSV reactivation may result in life-
threatening infections of the central nervous system [3,4]. Both
HSV-1 and HSV-2 infections are efﬁciently transmitted by sexual
route and genital herpes is one of the most prevalent sexually
transmitted infections (STIs) worldwide. Of note, genital ulcer
disease, primarily associated with HSV-2 infection, increases the
risk of HIV acquisition by damaging the genital mucosa; it induces
local inﬂammation and the production of cytokines and chemo-
kines that activate and recruit CD4þ HIV target cells [5e7].
Indeed, in resource-limited countries where both viruses are
highly prevalent, a high proportion of HIV infections can be
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prevent or treat HSV infections are expected to reduce rates of the
sexual transmission of HIV and should therefore be part of HIV-1
prevention programs [7,10e12]. At present, there are a number of
antiviral medications with activity against HSV-1 and HSV-2 and all
are nucleoside analogues. These include acyclovir, penciclovir and
their derivates, valacyclovir, and famciclovir. However the effec-
tiveness of antiviral therapy sometimes is limited by the develop-
ment of antiviral resistance and relative high toxicity [13].
There are no vaccines currently available to prevent and treat
HSV infection, but the pipeline is rich with candidates in various
phases of development (for a comprehensive and update review
see Ref. [14]) and studies directed at developing alternative ap-
proaches are underway; for instance, through the development of
topical microbicides able to protect the genital mucosa from HSV
(and HIV) acquisition and transmission. Easy-to-use microbicides,
able to prevent most common sexually transmitted viruses, should
be associated to PrEP strategy, that is mainly directed against HIV-1
and not able to prevent totally HSV infections [15].
On this regard, signiﬁcant progresses to the development of
effective microbicides against STI have been achieved with nega-
tively charged polyanions and dendrimers of different formulations
[16e20]. Unfortunately, most of these compounds did not pass
phase III clinical trials and one, a dendrimer with highly anionic
charged branches developed by Starpharma Pty Ltd (Melbourne,
Australia) has proved active against bacterial vaginosis in humans
and is currently under testing for efﬁcacy against STIs in Phase 3
trials [20,21].
Poly(amidoamine)s (PAAs) are a family of synthetic and highly
biocompatible polymers with a highly versatile structure [22]. They
are degradable polymers obtained by Michael-type polyaddition of
primary or bis secondary amines to bisacrylamides. Many PAAs
exhibit a combination of properties imparting them a considerable
potential in the biomedical ﬁeld. They are usually degradable in
water at a rate depending on their structure. Therefore, if injected,
they are bioeliminable [23]. Most PAAs are only moderately toxic
despite their polycationic nature. According to a number of tests,
the toxicity of most PAAs is signiﬁcantly lower than that of poly-L-
lysine (PLL) or polyethylenimine (PEI) [24]. Amphoteric PAAs car-
rying side carboxyl groups switch from a prevailingly anionic to a
prevailingly cationic state in a relatively small pH interval. Those
that at pH 7.4 are prevailingly anionic proved nontoxic and
nonhemolytic. By contrast, those that at the same pH are prevail-
ingly cationic showed signiﬁcant toxicity and hemolytic activity. An
interesting exception is the PAA named AGMA1, prepared by pol-
yaddition of monoprotonated (4-aminobutyl)guanidine (agmatine)
to BAC. The repeating unit of AGMA1 contains three ionizable
groups, a strong acid (pKa 2.3), a medium-strength base (pKa 7.4),
and a strong base (pKa 12.1). AGMA1, an amphoteric, but prevail-
ingly cationic polymer, proved nontoxic and nonhemolytic in vitro
within the entire pH range tested (4.0e7.4) [25e27].
In a previous work, we screened a minilibrary of PAAs against a
panel of DNA and RNA viruses to search for new antiviral chemical
entities. AGMA1 selectively inhibited a panel of viruses, including
HSV-1, HSV-2, and human papillomavirus-16 (HPV-16) [28], which
exploit cell surface heparan sulfate proteoglycans (HSPGs) as
attachment receptors. HSPGs consist of a protein core and glycos-
aminoglycan (GAG) side chains of unbranched sulfated poly-
saccharides, known as heparan sulfates, which are structurally
related to heparin. The interaction between positively charged
basic amino acids in HSV envelope and HPV capsid proteins and
negatively charged sulfated/carboxyl groups of cellular HSPGs has
been described [29,30] and is considered an attractive target for the
development of microbicides able to block infection by sexually
transmitted viruses [16].Polycationic dendrimers have been so far developed mainly for
the transfection of genetic material into eukaryotic cells for gene
therapy, an approach that has been found however to be burden by
the tendency of these dendrimers to bind to glycosaminoglycans of
the cells surface [31]. With these premises, some HSPG-targeting
polycationic dendrimers have been developed and assayed
in vitro against different viruses, showing promising features: the
peptide dendrimer SB105-A10, containing clusters of basic amino
acids, proved to be a potent inhibitor of cytomegalovirus [32], HSV-
1, HSV-2, a broad spectrum of genital HPV types, R5, and X4 HIV-1
and was found to exert its action mainly by binding to HS exposed
on the cell surface [33e35]. Accordingly, we have recently
demonstrated that AGMA1 interacts with immobilized heparin and
cellular heparan sulfates, and that this, in turn, is able to prevent
HPV attachment to the cell surface [36].
The aim of the present study was to elucidate the mechanism of
action of AGMA1 against HSV infection and assess its antiviral po-
tency and biocompatibility in preclinical models. The results show
AGMA1 to be a non-toxic inhibitor of HSV infectivity in cell cultures
and human-derived vaginal epithelium. Moreover, it signiﬁcantly
reduced the burden of infection of HSV-2 genital infection in mice.2. Materials and methods
2.1. Cells and viruses
African green monkey kidney cells (Vero) (ATCC CCL-81) were
purchased from American Type Culture Collection (ATCC; Mana-
ssas, VA). The culture medium was Eagle's minimal essential me-
dium (E-MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with
heat-inactivated 10% fetal calf serum (FCS) (Gibco/BRL) and 1%
antibioticeantimycotic solution (Zell Shield, Minerva Biolabs
GmbH, Berlin, Germany). The neurovirulent strains LV [37] and MS
(ATCC VR-540) of HSV-1 and HSV-2, respectively, were used for
most in vitro studies and all in vivo experiments. Both strains were
sensitive to Acyclovir (ACV). Two laboratory HSV-2 strains (ACV-r1
and ACV-r2) with phenotypic resistance to ACV were generated by
serial passage of the reference strain in the presence of increasing
ACV concentrations. The ﬂuorescence virus, HSV-1(GFP), encoding
GFP fused to the gH envelope glycoprotein was kindly provided by
Dr. E. Caselli, University of Ferrara, Italy. To generate viral stocks,
semiconﬂuent T175 ﬂasks of Vero cells were propagated in com-
plete E-MEM and inoculated with 1 PFU/cell of virus. After 6 h, cells
were fed with fresh E-MEM and cultured until cell lysis. Culture
ﬂuids were spun at 1200-g, and the pellets frozen-thawed three
times to release intracellular virions. Supernatants were then
clariﬁed, pooled, and ultracentrifuged to concentrate the virus as
previously described [38]. Pelleted virus was resuspended in 1/100
of the initial volume in saline and stored in small aliquots at80 C
until use. Viral titer of randomly picked frozen aliquots was
determined in vitro by plaque assay on Vero cells.2.2. EpiVaginal™ tissues
The EpiVaginal Tissue Model (VEC-100/VEC-100-FT) was pur-
chased from MatTek Corporation (Ashland, MA, USA) and consists
of Human 3-D Vaginal-Ectocervical Tissues cultured to form a
multilayered and highly differentiated tissue closely resembling the
epithelial architecture found in vivo. According to the supplier's
instructions, EpiVaginal cultures were seeded with the apical sur-
face exposed to air in 6-well plates containing 0.9 ml MatTek assay
medium (VEC-100-ASY) per well. Plates were incubated overnight
at 37 C in 5% CO2.
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Inbred C57Bl/6 mice were purchased from Harlan Italy (Cor-
rezzana, Milan, Italy) and housed and bred in a Biosafety Level 3
animal facility approved for mice detention and reproduction. Mice
were maintained on a 12/12 h dark/light cycle and handled ac-
cording to European (2010/63/EU) and Italian (26/2014) guidelines.
Since age and estrous cycle inﬂuence susceptibility to genital her-
pes and disease course [39], all in vivo experiments were carried out
in mice of 11 weeks of age and with their estrous cycle synchro-
nized with 2 mg depot medroxyprogesterone acetate (Depo-Prov-
era) inoculated subcutaneously 5 days before infection. All
manipulations were performed under deep anesthesia with 2 ml/
hg 2,2,2-tribromoethanol inoculated intraperitoneally. The project
was approved by the University of Pisa Ethical Committee for An-
imal Research.2.4. Reagents
AGMA1 and biotinylated AGMA1(b-AGMA1) were prepared as
reported elsewhere [28,36]. AGMA1 has an average molecular
weight of 10,100 and a polydispersity of 1.25. It is very soluble in
water at all pH values, but hardly soluble inmost organic solvents. It
is amphoteric with isoelectric point 10.2. The pKa values of the
carboxyl-, guanidine- and ter-amine- groups present in AGMA1
repeating unit are 2.25, 7.4 and >12, respectively. Therefore, in the
pH interval 5e10 each unit carries both one positive and one
negative charge, whereas the tert-amine group is >90% protonated,
that is, cationic at pH 6 and approximately 50% protonated at pH 7.4
[25e27,36]. Since AGMA1 is available in polydisperse preparations
with an average molecular mass not unequivocally determinable,
we quantitatively refer to the compound in mg/ml. Acyclovir (ACV),
2,2,2-tribromoethanol, gelatin, horseradish peroxidase-labeled
streptavidin, methylcellulose, crystal violet, sodium dodecyl sul-
fate (SDS), NP-40, sodium deoxycholate, a cocktail of protease in-
hibitors, Tween 20, glycine and Triton X-100 were purchased from
SigmaeAldrich (Milan, Italy). Conventional heparin (13.6 kDa) was
from Laboratori Derivati Organici S.p.A. (Milan, Italy). Heparinase II,
a glycosidase that digests the GAG moiety of HSPGs [40] was from
SigmaeAldrich (St Louis, MO). Depot medroxyprogesterone acetate
(Depo-Provera) was purchased from Pﬁzer Italia (Latina, Italy).
Chromogenic substrate ABTS was from Kierkegaard & Perry Labo-
ratories (Gaithersburg, MD). The anti-HSV-1/2 ICP27 MAb
(8.F.137B) and the anti-HSV-1 ICP8 MAb (clone 10A3) were from
Abcam (Cambridge, UK). The anti-HSV-1/2 gD MAb (clone 2C10)
was from Virusys Corporation (Taneytown, MD). The anti-actin
MAb was from Chemicon International (Billerica, MA). The anti-
mouse Ab conjugated to horseradish peroxidase, used in immu-
noblotting, was from Amersham Italia (Milan, Italy). The rabbit
polyclonal anti-HSV-2 antibody and the biotin-free polymer-con-
jugated secondary antibody, used in immunohistochemistry, were
fromDako (Glostrup, Denmark). Cyclophosphamide was purchased
from Baxter (Rome, Italy). All the other reagents and solvents are
commercially available and used as received.2.5. Preparation and characterization of AGMA1 solution
To prepare the polymer solution, a weighed amount of AGMA1
was added to a 2.4% glycerol aqueous solution in water. The pH of
the solution was corrected to 5.0 using a 0.1 M NaOH. AGMA1 so-
lutionwas characterizedmeasuring osmolarity and viscosity values
using a semi-micro osmometer K-7400 (Knauer) and a capillary
viscosimeter (Ubeholde) respectively. These parameters were
determined just prepared and after three months.2.6. Cell viability assay
Conﬂuent Vero cell cultures in 96-well plates were incubated
with MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] at
different concentrations and in triplicate. Cells were cultured as for
the in vitro antiviral assays and viability was determined using the
CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA)
according to the manufacturer's instructions. Absorbances were
measured using a Microplate Reader (Model 680, BIORAD) at
490 nm. The effect on cell viability of AGMA1 tested at different
concentrations was expressed as a percentage, by comparing the
absorbances of treated cells with those of cells incubated with
culture medium alone. The 50% cytotoxic concentrations (CC50s)
and 95% conﬁdence intervals (CIs) were determined using Prism
software (Graph-Pad Software, San Diego, CA).
2.7. AGMA1 binding to Vero cells assays
Monolayers of Vero cells in 96-well plates were incubated for
2 h at 4 C in phosphate-buffered saline (PBS) containing 0.1 mg/ml
CaCl2, 0.1 mg/ml MgCl2, and 0.1% gelatin, with sub-saturating
concentrations of b-AGMA1 (0.01 mg/ml or 0.1 mg/ml) in the
absence or presence of heparin (10 mg/ml). At the end of incubation,
cells were washed with PBS, and the amount of cell-associated b-
AGMA1 was determined with horseradish peroxidase-labeled
streptavidin (1/5000) and the chromogenic substrate ABTS. In
some experiments, cell monolayers were washed with PBS con-
taining 2 M NaCl, a treatment known to remove cationic poly-
peptides from cell surface HSPGs [41]. Alternatively, cells were
incubated with heparinase II (15 mU/ml) for 1 h at 37 C (an
experimental condition demonstrated to efﬁciently remove HSPGs
from the epithelial cells surface [36]) or left untreated before the
binding assay.
2.8. In vitro antiviral activity assays
2.8.1. HSV virus yield reduction assay
The assay is ﬁnalized to quantify the antiviral effect of com-
pound testing its effect on the production of infectious viruses. Vero
cells were seeded in 24-well plates at a density of 10  104 cells/
well and infected in duplicate with HSV-1 or HSV-2 at a multiplicity
of infection (MOI) of 0.01 plaque-forming units (PFU)/cell and in the
presence of serial dilutions of the compound. Following adsorption
at 37 C for 2 h, the virus inoculumwas removed and cultures were
grown in the presence of AGMA1 until control cultures displayed
extensive cytopathology. Supernatants were harvested and pooled
as appropriate 48e72 h after infection and cell-free virus infectivity
titers were determined in duplicate by plaque assay in Vero cell
monolayers. The end-point of the assay was the effective concen-
tration of compound that reduced virus yield by 50% (EC50)
compared to untreated virus controls.
2.8.2. HSV plaque reduction assay
The assay is ﬁnalized to quantify the antiviral effect of com-
pound testing its ability to reduce the number of viral plaques. Vero
cells were seeded in 24-well plates at a density of 10  104 cells/
well and infected at 0.001 MOI in the presence of different con-
centrations of compound for 2 h at 37 C, washed, and then overlaid
with 1.2% methylcellulose. After 24 h (HSV-2) or 48 h (HSV-1) of
incubation at 37 C, cells were ﬁxed and stained with 0.1% crystal
violet in 20% ethanol and viral plaques were counted. The concen-
tration of compound that reduced plaque formation by 50% (EC50)
was determined by comparing treated and untreated wells. PRISM
4 software (GraphPad Software, San Diego, California, U.S.A.) was
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calculate EC50 values. A selectivity index (SI) was calculated by
dividing the CC50 by the EC50 value.
2.8.3. Immunoblotting of viral proteins
The assay is ﬁnalized to evaluate the ability of AGMA1 to inhibit
the HSV-1 protein expression in treated-, infected-extracts of Vero
cells. Whole-cell extracts were prepared by resuspending pelleted
cells in lysis buffer containing 150 mM NaCl, 50 mM Tris-Cl (pH 8),
0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate and a cocktail of
protease inhibitors. Soluble proteins were collected by centrifuga-
tion at 15,000g. Supernatants were quantiﬁed and stored at 80 C
as described [42]. For immunoblotting, proteins were separated by
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to
Immobilon-P membranes (Millipore). Membranes were then
incubated with blocking buffer consisting of 5% nonfat dry milk in
10 mM Tris-Cl (pH 7.5)e100 mM NaCle0.1% Tween 20 and immu-
nostained with anti-HSV-1/2 MAbs against ICP27, ICP8 and gD
proteins, and the anti-actinMAb. Immunocomplexeswere detected
using a sheep anti-mouse immunoglobulin Ab conjugated to
horseradish peroxidase, and visualized using enhanced chem-
iluminescence (Super Signal; Pierce), according to the manufac-
turer's instructions.
2.8.4. Virus inactivation assay
The assay evaluates the virucidal activity of compound. AGMA1
(33 mg/ml) was added to aliquots of 105 PFU HSV-1 or HSV-2 and
incubated at either 4 or 37 C for 2 h. After incubation, samples
were titrated on Vero cells at high dilutions, at which the com-
pound was not active.
2.8.5. Cell pre-treatment assay
The assay evaluates the antiviral activity of compound when
administered before infection. Cells were exposed to different
concentrations of AGMA1 in a 24-well plate at 4 C or 37 C for two
hours. After washing, cells were infected with HSV-1 or HSV-2 at
0.001 MOI for two hours, washed and treated as for plaque
reduction assay.
2.8.6. Attachment assay
The assay evaluates the ability of compound to inhibit the
attachment of virus to cells. The assay was performed as described
previously [43]. Prechilled Vero cells were treated with AGMA1 or
heparin for 30min at 4 C and then infectedwith HSV-1 or HSV-2 at
0.004 MOI for 2 h at 4 C in presence of the compound. After three
washes with cold MEM to remove unbound virus, cells were
overlaid with 1.2% methylcellulose and shifted to 37 C. After 24 h
(HSV-2) or 48 h (HSV-1) of incubation, cells were stained and viral
plaques counted. Cells infected in absence of compound were
arbitrarily set at 100% of infection and served as positive control. To
examine viral attachment without entry, cells were incubated at
4 C and treated for two minutes with cold acidic glycine (100 mM
glycine, 150 mM NaCl, pH 3) to inactivate attached virus, resulting
in 100% inhibition of infection.
2.8.7. Entry assay
The assay evaluates the ability of compound to inhibit the entry
of virus into cells. HSV-1 or HSV-2 at 0.004 MOI was adsorbed for
2 h at 4 C on prechilled conﬂuent Vero cells. Cells were then
washed with cold MEM three times to remove unbound virus,
treated with different concentrations of AGMA1 or Heparin, and
incubated for three hours at 37 C. Outer virions were inactivated
with acidic glycine for 2min at room temperature as described [43].
Cells were washed with warm medium three times and treated as
for plaque reduction assay.2.8.8. Binding assay
The assay evaluates the ability of compound to inhibit the
binding of virus to cells. Cells were pre-incubated with AGMA1 or
Heparin for 30 min or left untreated (control) at 4 C and then
infected for 2 h at 4 C with 5 MOI HSV-1 as described [44]. Cells
were then washed four times with PBS and lysed as described
below in Immunoblotting section. HSV was detected with a MAb
against the Glycoprotein D. Actin was stained as input control.
2.8.9. Post-entry infection assay
The assay evaluates the antiviral activity of compound when
administered after infection. Vero cells monolayers in 96-well plate
were infected with HSV- 1(GFP), HSV-1 or HSV-2 for two hours at
37 C, followed by two gentle washes to remove unbound virus.
Increasing AGMA1concentrations (at 0 h post-infection) or 100 mg/
ml (at 1, 2, 3, 6 h post-infection) were then added to cultures in 1.2%
methylcellulose medium. After incubation at 37 C for 24 h (HSV-2)
or 48 h (HSV-1), cells were ﬁxed and stained with 0.1% crystal violet
in 20% ethanol to count the number and measure the size of viral
plaques. Plaque size was measured with a Leica inverted micro-
scope equipped with a Bresser MikroCam microscope camera and
MikroCamLab software (Rhede, Germany). Plaques of HSV-1(GFP)
were analyzed with an inverted Zeiss LSM510 ﬂuorescence micro-
scope and measured using with ImageJ software. To assess the ef-
fect of AGMA1 added after infection, a virus yield reduction assay
was performed and EC50 determined by comparing drug-treated
and untreated wells, as described above.
2.9. Antiviral assay at acidic pHs
To evaluate the stability of AGMA1 at different pHs [45], the
compound was incubated in phosphate-buffered saline solutions of
pH 3, pH 5, pH 7, for 2 h at 37 C as previously described [45].
Thereafter, different concentrations of pH-treated AGMA1 were
incubated with conﬂuent Vero cell monolayers for 1 h at physio-
logical pH. Cells were then infected at physiological pH with HSV-2
at an MOI of 0.001 for two hours, washed and treated as for plaque
reduction assay.
2.10. Assays on EpiVaginal™ tissues
2.10.1. Viability assay
EpiVaginal tissues were evaluated using the MTT ET-50 Tissue
Viability Assay (MatTek Corporation), according to manufacturer's
instructions. AGMA1 (100 mg/ml) was added to the cell culture
insert placed on top of the EpiVaginal samples and incubated for
30 min, 1, 4, and 18 h in duplicate. At the end of incubation, any
liquid remaining on top of the tissuewas decanted and inserts were
washed with PBS to remove any residual material. Tissues were
then processed according to the MTT protocol and read at 570 nm
using an ELISA plate. Tissues were incubated with 1.0% Triton X-100
and ultrapure water as positive and negative controls, respectively.
The ET-50 value refers to the time required to reduce tissue viability
to 50% and was determined using Prism software. According to the
manufacturer an ET50 value > 18 h indicates that a compound does
not cause vaginal irritation and can be used for feminine hygiene
products.
2.10.2. Cytotoxicity assay
Any cytotoxic effect of AGMA1 (100 mg/ml) on EpiVaginal tissues
was evaluated by analyzing the release of lactate dehydrogenase
(LDH) into culture medium, which increases in a manner that is
proportional to the number of dead cells. The LDH cytotoxicity
assay was performed according to manufacturer's protocol
(TAKARA bio inc, Japan).
M. Donalisio et al. / Biomaterials 85 (2016) 40e53442.10.3. Analysis of inﬂammatory response
This was evaluated bymonitoring cytokine IL-1a release into the
culture medium of EpiVaginal tissues treated with AGMA1 (100 mg/
ml) for 30 min, 1, 4, and 18 h, as previously reported [46]. After
incubation, the concentration of IL-1a in the culture medium was
measured using the IL-1 alpha ELISA KIT, according to the manu-
facturer's instructions (Bender Medsystem). The concentration of
IL-1a was calculated by interpolation from a standard calibration
curve.
2.10.4. Antiviral assays
EpiVaginal Tissue cultures were pre-incubated with 100 ml
medium containing 100 mg/ml AGMA1. Mediumwas applied to the
apical surface and cells were incubated at 37 C for 2 h. After pre-
incubation, the medium was removed and cultures were infected
with 1000 pfu HSV-2 at 37 C for 2 h in the presence of AGMA1.
Cultures were washed apically with 100 ml medium, incubated at
37 C, and fed each day via the basolateral surface with 0.9 ml
medium. Viruses were harvested at 24, 48, 72 and 96 hpi by adding
100 ml medium per well to the EpiVaginal Tissue apical surface that
was allowed to equilibrate for 30 min. Viral suspension was then
collected and stored at 80 C until viral titers were determined by
plaque assay in Vero cell monolayers. Harvesting was performed
daily.
2.10.5. Detection of HSV-2 by immunohistochemistry
HSV-2 was detected on EpiVaginal cultures by immunohisto-
chemistry using a polyclonal anti-HSV-2 antibody. Brieﬂy, Epi-
Vaginal tissue cultures were ﬁxed in buffered formalin, properly
oriented, and embedded in parafﬁn together with adherent
collagen membranes. Tissue sections were incubated with the anti-
HSV-2 antibody or stained with hematoxylin and eosin. Tissues
were processed for antigen retrieval in citrate buffer using a dedi-
cated pressure cooker (1 cycle for 50 at 125 C, followed by 10 s at
90 C). After incubationwith the primary antibody (1:500 dilution),
the reaction was visualized using a biotin-free polymer-conjugated
secondary antibody. In positive samples, the antibody showed
cytoplasmic and nuclear immunoreactivity, mostly recognizable in
cells of the superﬁcial layers. Several sections were analyzed for
each experimental condition.
2.11. Analysis of antiviral activity in vivo
2.11.1. Titration of viral stocks in vivo
All animals were treated in parallel and grouped at random.
Eleven-week-old mice were infected via vagina following estrous
cycle synchronization. To facilitate absorption, vaginas were pre-
swabbed with a dry tipped swab immediately prior to instillation
of 10-fold dilutions of viral stocks. Animals were then examined
daily for clinical signs of infection that were graded according to a
ﬁve-point scale: 0, no signs; 1, slight genital erythema and/or
edema; 2, papules, ulcers and/or swelling; 3, fused ulcers, purulent
genital lesions and/or hind limb paralysis; 4, death [47]. Titrations
were performed using 5e8 animals/virus dilution. Lethal dose 50%
(LD50) was calculated using the Reed-Müench method. One and 10
LD50 roughly corresponded to 106 and 108 PFU, respectively. Ani-
mals that survived despite paralysis or other irreversible lesions
were euthanized by cervical dislocation under anesthesia.
2.11.2. Analysis of AGMA1 efﬁcacy
The antiviral activity of AGMA1 against HSV-1 and HSV-2
vaginal infections was assessed by dispensing AGMA1 (1 mg/ml)
in a 2.4% glycerol aqueous solution, as described previously. AGMA1
(10 ml) was applied to pre-swabbed vaginas at varying time-points
prior to infection (15 se30 min). The “Vehicle” group, referring tothe glycerol aqueous solution used to prepare the AGMA1 solution,
was treated the sameway. Infections were performedwith 1,10 and
100 LD50. Animals were monitored for clinical signs of infection for
about 4 weeks post-infection. Immunosuppression was achieved
with an intraperitoneal bolus of 350 mg/kg cyclophosphamide that
depleted the circulating lymphocytes in a mouse by approximately
90% within 1 day, as described [38].
2.11.3. Detection of HSV-2 DNA genome in nervous tissues
Sacral nerves and genital gangliawere protease digested and the
DNA extracted using the QIAamp DNAmini kit, as recommended by
the manufacturer (Qiagen, Milan, Italy). Molecular analysis was
carried out by performing a HSV-2 speciﬁc nested polymerase
chain reaction (PCR) as previously described [48]. The outer and
inner PCR primer pairs were: forward 6AF (50-TCAGCC-
CATCCTCCTTCGGCAGTA-30) e reverse 6BR (50-GATCTGGTACTC-
GAATGTCTCCG-30) and forward 6CF (50-
AGACGTGCGGGTCGTACACG-30) e reverse 6DR (50-
CGCGCGGTCCCAGATCGGCA-30), respectively. The ampliﬁcation
proﬁle (denaturation: 94 C for 2 min; cycling: 94 C for 1 min,
56 C for 1min, and 72 C for 1mine5 cycles; cycling: 94 C for 45 s,
56 C for 30 s, 72 C for 1 mine40 cycles; ﬁnal extension 72 C for
15 min) was the same for both PCRs except that the second
ampliﬁcation proﬁle was diminished from 40 to 30 cycles. Ampli-
cons were examined by agarose gel (1%) electrophoresis.
2.12. Statistical analysis
All data were analyzed using GraphPad Prism 5.00 (GraphPad
Software). Infectivity and measurement of plaque sizes in the
presence and absence of AGMA1 were compared by one-way
analysis of variance (ANOVA) followed by a Bonferroni test if P
values showed signiﬁcantly differences. Results were expressed as
means ± standard deviations. Results of the direct binding test of
the compound to the cell surface, were analyzed by Student's t test.
The Fisher exact test was applied to evaluate the in-vivo test results.
Differences in number of disease-free animals of AGMA1 vs vehicle
and naïve groups were assessed for statistical signiﬁcance using
heterogeneity of contingency tables. A value of p < 0.05 was
considered signiﬁcant.
3. Results
3.1. AGMA1 solution characterization
The AGMA1 solution showed a pH ¼ 5.0, a viscosity ¼ 1.07 cP
and an osmolarity ¼ 340 mOs, values suitable for a vaginal appli-
cation. These parameters did not change after three months from
the preparation.
3.2. Antiviral activity of AGMA1 against HSV-1, HSV-2, and
ACVeresistant strains in vitro
AGMA1 was evaluated in vitro for antiviral activity against HSV-
1, HSV-2, and two HSV-2 ACVeresistant strains by plaque reduction
assays. Assays were performed by incubating cells in the presence
of decreasing concentrations of compound (ranging from 100 mg/
mL to 0.13 mg/mL) during and after viral adsorption. As shown in
Table 1, AGMA1 was active against wild-type HSV-1 and HSV-2
with EC50 values of 3.05 and 1.3 mg/ml, respectively, similar to
previously reported values [28]. As expected, the resistant strains
exhibited elevated EC50s for ACV [260 mM and 319 mM (58.5 mg/ml
and 71 mg/ml), respectively (data not shown in Table 1)]. By
contrast, they were susceptible to AGMA1 inhibitory activity.
Microscopic inspection and cell viability assays showed that
Table 1
AGMA-1 antiviral activity against wild-type and ACV resistant HSV strains.
Virus EC50a(mg/ml) CC50a(mg/ml) SIb
HSV-1 3.05 ± 1.22 >300 >98.36
HSV-2 1.30 ± 1.15 >300 >230.76
HSV-2 ACV-r1 0.69 ± 1.34 >300 >434.78
HSV-2 ACV-r2 1.00 ± 1.98 >300 >300.00
a The EC50 (effective compound concentration that reduced viral plaque forma-
tion by 50%) and the CC50 (50% cytotoxic concentration) are expressed as the mean
(mg/ml) ± S.D. of three independent experiments.
b SI ¼ selectivity index, determined by the ratio of CC50 to EC50.
Fig. 2. AGMA1 inhibits early and late HSV gene expression. Vero cells were infected
with HSV-1 in the absence or presence of AGMA1 or Acyclovir during infection. Mock:
uninfected cells. Proteins were extracted and analyzed by western blotting using the
following antibodies: anti-ICP27, anti-ICP8, and anti-gD. Actin served as an internal
control.
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tested (300 mg/ml), demonstrating that the antiviral activity was
not a consequence of cell toxicity.
The antiviral effect of AGMA1 was conﬁrmed further by means
of the yield reduction assay (see Materials and Methods section), a
stringent test that allows multiple cycles of viral replication to
occur before measuring the production of infectious viruses. The
doseeresponse curves reported in Fig. 1 show that AGMA1 effec-
tively reduces the HSV-1 and HSV-2 yield, with EC50 values equal to
0.74 mg/ml and 1.14 mg/ml, respectively.3.3. Investigation of AGMA1 mechanism of action
AGMA1's activity against ACV-resistant strains, as summarized
in Table 1, may suggest that AGMA1 acts through a different
mechanism of action to that of ACV. To substantiate this hypothesis,
the effect of AGMA1 and ACV on the expression of immediate-early,
early and late viral proteins (ICP27, ICP8, and gD, respectively) was
investigated by western blotting. As shown in Fig. 2, ACV
completely suppressed the expression of the late protein gD. This
ﬁnding was expected as ACV is a known inhibitor of viral replica-
tion, an event that occurs prior to late gene expression. In contrast,
in addition to gD, AGMA1 also completely inhibited the expression
of early viral proteins, indicating that AGMA1 may either inactivate
the virus particle or inhibit an early step of the viral replication
cycle that immediately precedes early gene expression (i.e. virus
attachment or entry).
We ﬁrst investigated whether the antiviral action of AGMA1 is
exerted via the direct inactivation of HSV-1 or HSV-2 virus particles.
To this end, we performed the virus inactivation assay described inFig. 1. AGMA1 reduces virus yield in Vero cells. Vero cells were infected at a MOI of
0.01 with clinical isolates of HSV-1 or HSV-2 and treated with increasing doses of
AGMA1 during viral adsorption. Cells were exposed to the drug concentrations until an
extensive viral cytopathic effect was observed in the untreated controls. The super-
natants from cell suspensions were assayed for their infectivity by standard plaque
reduction assay. Values are the means ± SD of three separate experiments performed
in duplicate.section 2.8.4. As reported in Table 2, the virus titers of samples
treated with AGMA1 did not signiﬁcantly differ from those deter-
mined for untreated samples (P < 0.05), indicating that the com-
pound does not inactivate extracellular virus particles.
Next, we investigated whether AGMA1 could interfere with the
early stages of viral infection. In a ﬁrst series of experiments, the
viral attachment assays described in section 2.8.6. were performed.
As shown in Fig. 3A, under these experimental conditions AGMA1
inhibited HSV1 and HSV-2 infection with EC50s (3.09 mg/ml and
5.66 mg/ml, respectively) that are comparable to those measured in
the classic viral plaque assay suggesting that the antiviral activity of
AGMA1 depends on its capacity to inhibit the attachment of the
viruses to the cell surface. To substantiate this interpretation, cells
from the attachment assay were lysed after washing and processed
for immunoblotting, performed using a MAb directed against the
viral glycoprotein gD, to detect the amount of viral particles bound
to the cell surface. Heparin was used in this assay as a positive
control, being a known inhibitor of HSV attachment, which acts by
competing with cell-surface HSPGs for virus binding [49,50]. As
reported in Fig. 3B, both AGMA1 and heparin inhibited HSV-1
infection. In a second series of experiments, we explored the abil-
ity of AGMA1 to prevent HSV entry using the entry assay described
at section 2.8.7. As reported in Fig. 3A, AGMA1 did not affect the
capacity of prebound HSV-1 or HSV-2 virus to infect cells at any
dose examined. Taken together, these data indicate that AGMA1
does not inactivate HSV-1 or HSV-2; instead it acts by inhibiting
virus attachment, but not entry.
Antiviral compounds that block virus attachment to target cells
mainly act by binding to (and sequestering) virions in the extra-
cellular environment [16] or by binding (and masking) virus re-
ceptors on the surface of target cells [33]. To explore the possibility
that AGMA1 acts directly on Vero cells, the pre-treatment assay
described at section 2.8.5. was performed. As reported in Fig. 4,
AGMA1 inhibited infection by both HSVs in a dose responseTable 2
Effect of AGMA1 on virus infectivity.
Incubation condition AGMA1a Virus titer (PFU/ml)b
Temp (C) Duration (h) HSV-1 HSV-2
37 0 e 4.00  105 1.19  105
37 0 þ 3.30  105 1.68  105
37 2 e 4.19  104 4.50  104
37 2 þ 3.70  104 3.54  104
4 2 e 6.02  105 1.57  105
4 2 þ 9.24  105 9.82  105
a Concentration: 33 mg/ml.
b Virus titers at high dilutions at which the compound was not active. The titers
are mean values for experiments performed in triplicate.
Fig. 3. AGMA1 prevents attachment but not entry of HSV to target cells. (A) Anti-HSV-
1 activity and anti-HSV-2 activity in attachment and entry assays by Plaque Reduction
Assay. Attachment: cells were pretreated with AGMA1 for 30 min at 4 C and then
infected for 2 h at 4 C. Entry: prechilled cells were infected with viruses for 2 h at 4 C,
then washed and treated with AGMA1 for 3 h at 37 C; unpenetrated virions were
inactivated by acidic glycine treatment. Values are the means ± SD of three separate
experiments performed in duplicate. (B) Binding assay: cells were preincubated with
AGMA1 or heparin (100 mg/ml) for 30 min and then infected at an MOI of 5 with HSV-1
for 2 h. Columns: (1) uninfected; (2) infected; (3) infected in presence of heparin; (4)
infected in the presence of AGMA1. Attached virions were detected by Immunoblot-
ting, using a Mab directed against the glycoprotein gD. Actin served as an internal
control.
Fig. 4. Vero cells pre-treated with AGMA1 are less susceptible to HSV infection. Cells were p
are the means ± SD of three separate experiments performed in duplicate.
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and HSV-2, respectively. As expected, heparin (that acts by bind-
ing directly to the virus) was inactive under these experimental
condition. Taken together, these data suggest that AGMA1 reduces
cells susceptibility to virus infection by tethering to the cell surface
and possibly masking HSV receptors.3.4. AGMA1 interacts with the cell surface via HSPGs
Based on the above results we investigated the effective capacity
of AGMA1 to bind to the cell surface of Vero cells via HSPGs (see
methods, paragraph 2.7). As shown in Fig. 5A, AGMA1 effectively
binds to the surface of Vero cells in a dose-dependent and saturable
manner. Moreover, binding could be disrupted by washing with
2 M NaCl (a treatment known to disrupt the binding of cationic
molecules to HSPGs [41]) and it could be prevented by a molar
excess of heparin (a structurally related antagonist of HSPGs) and
by cell treatment with heparinase (an enzyme that removes the
heparan sulfate chains from cell surface-associated HSPGs)
(Fig. 5B). Taken together, these results provide strong evidence that
AGMA1 interacts with the cell surface via HSPGs. However, the
partial inhibition of AGMA1 binding to heparinase II-treated cells
also suggest that other receptors beside HSPG may bind AGMA1.3.5. Effect of AGMA1 on the cell-to-cell spread of HSV
To determine whether AGMA1 interferes with cell-to-cell virus
spreading, post-entry assays, described at section 2.8.9., were per-
formed. As shown in Fig. 6A, the area of HSV-1(GFP) plaques,
assessed by ﬂuorescence microscopy, decreased in a dose-
dependent manner in AGMA1-treated cells, and at a concentra-
tion of 100 mg/ml singly infected cells were mainly seen. In contrast
to the signiﬁcant reduction in plaque size, quantiﬁed using ImageJ
software, no signiﬁcant reduction in the number of HSV plaques
was observed. Similar results were obtained for wild-type HSV-1
(Fig. 6B) and HSV-2 (Fig. 6C). A process of fusion of plasma mem-
brane of an infected cell with that of a neighboring uninfected cell,
is thought to occur during cell-to-cell spread. Recently, syndecans,
single transmembranous heparan sulfate proteoglycans, have been
demonstrated to contribute to HSV-1 induced cell-to-cell fusion
and lateral spread [51]. Inhibition of cell-to-cell spread of HSV by
AGMA1, it's probably due to its ability to interact with HSPG and
consequently mask the core protein of syndecan-1, involved in
membrane fusion. Viral yield reductions assays also demonstrated
that addition of AGMA1 after infection heavily affected viral pro-retreated with AGMA1 or heparin for 2 h at 37 C before viral adsorption period. Values
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Fig. 5. HSPGs contribute to AGMA1 binding to Vero cells. Vero cells were incubated with increasing concentrations of b-AGMA1 alone (panel A) or subjected to the following
treatments in the presence of b-AGMA1 at a ﬁxed concentration (0.1 mg/ml) (panel B): i) incubated with b-AGMA1 alone. ii) incubated with b-AGMA1 and then washed with PBS
containing 2 M NaCl; iii) incubated with b-AGMA1 in the presence of a molar excess (10 mg/ml) of heparin. iv) pre-treated with heparinase before b-AGMA1 incubation. The amount
b-AGMA1 bound to Vero cell surface was then measured and is reported in panel B. In panel A, each point is the mean ± SEM of 3 independent determinations in duplicate. In panel
B, data are expressed as the percentage of b-AGMA1 bound to control cells and each point is the mean ± SEM of 2e4 independent determinations in duplicate. * ¼ p < 0.05, and
** ¼ p < 0.01 with respect to control treated with b-AGMA1 alone, Student's t test.
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3.98 mg/ml (HSV-2).3.6. AGMA1antiviral activity is not affected by acidic pHs
Analysis of the mechanism of action of AGMA1 demonstrated its
ability to prevent HSV infection. To evaluate its potential as
candidate microbicide for preventing genital HSV-2 infections, the
antiviral activity in presence of speciﬁc physiological properties of
the vagina, such as acidic pHs, was considered. To this end, AGMA1
was incubated in buffers of different pHs for 2 h at 37 C, and the
antiviral activity was evaluated by viral plaque reduction assays at
physiological pH. Results demonstrated that the acidic treatment
did not affect the activity of AGMA1, since the inhibitory effect
against HSV-2 at pH 3 (EC50: 3.86 mg/ml) and at pH 5 (EC50: 2.28 mg/
ml) was similar to that observed for compound incubated at neutral
pH (EC50: 2.32 mg/ml).3.7. Antiviral activity of AGMA1 in EpiVaginal tissue
To investigate the effects of AGMA1 in amodel that more closely
resembles the in vivo environment, the EpiVaginal system was
employed. Brieﬂy, this system consists of human-derived ectocer-
vical epithelial cells grown on a collagen-coatedmembrane to form
a multilayered and highly differentiated tissue that closely re-
sembles the vaginal mucosa. EpiVaginal cultures were treated
apically with 100 mg/ml AGMA1 for two hours, and then infected
with 1000 pfu HSV-2. AGMA1 totally inhibited the virus emerging
from the apical surface at different days post infection (Fig. 7A).
Complete inhibition of viral infection was conﬁrmed by immuno-
histochemistry, using an HSV-2-speciﬁc antibody, at 3 days post-
infection. As shown in Fig. 7B, sections derived from the infected
tissue exhibited strong staining for the expression of HSV-2 anti-
gens (Fig. 7Bb). In contrast, no HSV-2 positive cells were observed
in the uninfected tissue (Fig. 7Ba). AGMA1-treated samples did not
show a HSV-2 signal (Fig. 7Bc). In addition, pre-treatment of tissues
with AGMA1 reduced viral infection at 2 days post infection (84%
inhibition; data not shown).
Since reconstituted tissues are ideally suited for toxicology
studies [52], we also tested biocompatibility and the inﬂammatorypotential of AGMA1. Brieﬂy, AGMA1 (100 mg/ml) was applied to the
apical surface at the air-tissue interface for 1, 4, or 18 h at 37 C, and
tissues were subsequently analyzed for (i) the reduction of tetra-
zolium salt (MTT) to colored formazan compounds in order to study
the metabolic activity of the living cells; (ii) lactate dehydrogenase
(LDH) release, to measure the accumulation of dead cells; and (iii)
the release of interleukin-1 alpha (IL-1 alpha) to evaluate the in-
ﬂammatory activation of cells (see Materials and Methods for
further details). As reported in Table 3, AGMA1 did not affect
viability, and Effective-Time 50 (ET-50), i.e. the time necessary to
reduce cell viability by 50% was greater than 18 h and indistin-
guishable to that observed in naïve cells. Furthermore, no differ-
ence in the release of LDH cytoplasmic enzyme was observed
between AGMA1-treated and untreated tissues, suggesting that no
cytoplasmic damage had occurred. Finally, there was no signiﬁcant
difference in the level of the proinﬂammatory cytokine IL-1 alpha
(Table 3) compared to untreated samples.3.8. Assessment of AGMA1 antiviral activity in vivo
Finally, we sought to conﬁrm our in vitro ﬁndings and assess
AGMA1 efﬁcacy in vivo by analyzing HSV infection by venereal
spread, the chief route of HSV transmission in industrialized and
developing countries [11,53]. Here, we used an established murine
animal model of HSV genital infection [38] and 100 mg/ml AGMA1, a
concentration that was well-tolerated in mice and able to abolish
viral infectivity in the EpiVaginal tissue. Tests were aimed to: 1.
Determine the best timing of administration before infection; 2.
Evaluate efﬁcacy against HSV-1 and HSV-2 strains; 3. Assess the
breadth of antiviral activity toward escalating infectious doses; 4.
Investigate whether animals that exhibited no visible signs of
infection had subclinical infection. All experiments were performed
using 6e12 animals/group, a number suitable for statistical anal-
ysis, and lasted about four weeks, i.e. a time sufﬁcient to monitor
the complete course of the disease. Depending on infectious dose
and ability of immune system to restrain viral spread, infection is
usually self-limited, clinically manifests at day 5e6, and disappears
within two-three weeks [38]. Clinical signs can be negligible
(subclinical or asymptomatic infection), severe and rapidly pro-
gressing to paralysis and death, or evolve in a persistent disease
Fig. 6. AGMA1 inhibits HSV at a post-entry level. Monolayers of Vero cells were infected with HSV-1(GFP) (A), clinical isolates of HSV-1 (B), or HSV-2 (C) in the absence of AGMA1.
The inoculum was removed at 2 h post-infection, and cells were left untreated (a) or incubated in the presence of the following concentrations of AGMA1: (b) 100 mg/ml, (c) 33 mg/
ml, (d) 11 mg/ml, (e) 3.6 mg/ml, or (f) 0.13 mg/ml. Plaque formation was assessed 24 or 48 h after infection. The bar charts show the plaque area and the plaque count of HSV-1(GFP),
HSV-1 and HSV-2, as a function of AGMA1 concentration. The data presented are means plus standard deviations for triplicates. * P < 0.05.
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animal. Clinical outcome was scored according to a standard ﬁve-
point scale [38,47] as described in Material and Methods.
The most effective timing of AGMA1 administration was deter-
mined using four groups of animals (six animals/group) that were
infected via the vagina with 1 LD50 of HSV-1 and were either left
untreated (naïve control) or treated with AGMA130min, 15 min, or
15 s before infection. As shown by Fig. 8A, which depicts the
percent of animals that remained disease-free throughout the
observation period, all naïve controls developed infection, mani-
festing overt symptoms from day 6, and two animals died on day
10e11. Of the 4 surviving animals, 3 had recovered by day 13, andone was still sick when the experiment was terminated. Of the
animals treated with AGMA1 30 min before infection, 3 were
transiently infected and fully recovered by day 12, 1 died on day 9,
and 2 showed no symptoms throughout the course of the follow-up
period. In contrast, of the groups of animals pretreated with
AGMA1 at 15 min and 15 s before infection, 3 and 4 animals
remained disease-free, respectively, and 3 and 2 developed a
transient and mild disease (clinical score  2). Although groups
were too small to draw ﬁrm conclusions, pretreatment at 15 s and
15 min clearly delayed and reduced clinical manifestations
(Fig. 8A). Compared to the naïve group, percent of disease-free
animals of these two groups reached statistical signiﬁcance at day
Fig. 7. AGMA1 inhibits HSV-2 infection in EpiVaginal tissue. (A) Antiviral activity of AGMA1 in EpiVaginal tissue infected with 1000 pfu of HSV-2. (B) Immunohistochemistry of
control tissue (a), HSV-2-infected tissue (1000 PFU) (b), and HSV-2-infected tissue treated with 100 mg/ml of AGMA1 at 3 days post-infection (c) using a speciﬁc antibody to HSV-2
(brown signal). The pictures shown are representative of analyzed sections (5e12 sections analyzed per condition). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Table 3
Evaluation of the irritation potential of 100 mg/ml of AGMA1 in the EpiVaginal tissue model.
Conditions % Viability LDH release (A) IL-1 alpha release (pg/ml)
Untreated (1 h) 100 0.75 ± 0.06 8.4 ± 2.1
AGMA1 (1 h) 115.07 ± 12.90 0.74 ± 0.02 8.2 ± 1.9
Untreated (4 h) 100 0.76 ± 0.03 10.8 ± 1.0
AGMA1 (4 h) 109.59 ± 0.04 0.73 ± 0.03 9.9 ± 1.3
Untreated (18 h) 100 1.80 ± 0.04 31.5 ± 6.2
AGMA1 (18 h) 67.04 ± 10.75 1.46 ± 0.02 32.9 ± 1.4
M. Donalisio et al. / Biomaterials 85 (2016) 40e53 497 post infection (p < 0.002, data not shown). This result indicates
that AGMA1 exerts similar antiviral activity when applied within
this period of time. In all subsequent experiments, we thus applied
AGMA1 15 min before infection.
We next assessed whether AGMA1 protects against both HSV-1
and HSV-2 strains. For these experiments we used 36 animals that
were split in three groups: naïve, AGMA1, and Vehicle, i.e. animals
treated with AGMA1 carrier. After administration of AGMA1 and
Vehicle, animal groups were further subdivided into two groups
and infected with 1 LD50 HSV-1 or HSV-2. Five animals of the naïve/
HSV-1 group become overtly infected and 1 showed no symptoms.
Of the infected animals, 2 died on day 11 and 3 fully recovered. All
naïve/HSV-2 animals acquired infection, 3 died on day 11 and 2 still
showed disease symptoms at the end of observation period
(Fig. 8B). No signiﬁcant differences were observed between Vehicle
and Naïve groups. AGMA1 reduced the outcome of disease of the
two infections. In both AGMA1/HSV-1 and AGMA1/HSV-2 groups, 2
animals showed no symptoms, 3 animals were transiently infected,
and 1 animal died. Compared to the naïve group, the difference in
numbers of disease-free animals was statistically signiﬁcant for
AGMA1/HSV-2 group (p < 0.05), this was not the case for HSV-1 as
only 5/6 naïve animals became sick and, in general, showed a
milder course of infection (Fig. 8B).
Because of similar efﬁcacy against the two strains, higher viru-
lence of HSV-2 strain, higher incidence of genital HSV-2 infections
in humans, and to limit in vivo tests, analysis of AGMA1 potency
against escalating doses was performed with HSV-2. For this
experiment we used 10 animals/group and 1, 10, and, 100 HSV-2
LD50. As expected, clinical grading and mortality rate increased
with infectious dose; 1 LD50 infected 9/10 and killed 3/10 animals of
Naïve group, and infected and killed 9/9 and 5/9 animals of Vehicle
group (one animal was found dead at day 2 post infection for un-
known reasons); 10 LD50 infected all animals of both groups and
killed 4/10 and 6/10 animals of Naïve and Vehicle groups, respec-
tively; 100 LD50 infected and killed all animals of both groups
except 1 naïve that fully recovered at day 18 post infection. TheAGMA1 group challenged with 1 LD50 yielded: 5 animals totally
protected, 4 mildly and transiently infected, and 1 still sick at the
end of observation period. Statistical analysis showed that this
group performed signiﬁcantly better compared to Naïve and
Vehicle at p < 0.05 (Fig. 8C). Pretreatment with AGMA1 and chal-
lenging with 10 LD50 resulted in 3 animals fully protected, 4 tran-
siently infected, 1 chronically infected, and 1 death. These results
were, at same time, signiﬁcantly different compared to control
groups at p < 0.0001. Finally, AGMA1 pretreatment did not spare
animals from infection with 100 LD50 but, among the 6 surviving
animals, 4 were transiently infected and 2 still sick at the end of the
observation period. Whereas the difference in percent disease-free
animals reached statistical signiﬁcance only at onset of disease and
end of experiment, this was statistically signiﬁcant by comparing
mortality rate by day 10 post infection (p < 0.01) (Fig. 8C and data
not shown). This experiment demonstrated that AGMA1 protects
against disease at low to moderate infectious doses, and lessens
clinical consequences of a very high input dose (100 LD50), an in-
fectious load unlikely to ﬁnd in human transmission.
The last set of in vivo experiments was aimed to assess whether
the animals that had no clinical signs underwent subclinical (nearly
or completely asymptomatic) infection as it frequently occurs in
nature [53,54]. To this end, Naïve, Vector, and AGMA1 groups (11
animals/each) were challenged with 10 LD50 HSV-2, monitored for
four weeks, left untreated for two months, and ﬁnally immuno-
suppressed with a bolus of cyclofosfamide to induce reactivation of
latent infection. At four weeks post infection, 4 AGMA1 and 1 naïve
mice resisted or underwent subclinical infection; remaining ani-
mals were either dead or still sick (Table 4). One AGMA1 mice died
at day 3 post infection for unknown reasons as it showed no clinical
symptoms. As observed here, as well as in a previous study [38],
cyclofosfamide treatment depleted circulating lymphocytes by
approximately 90% within 1 day and left the animals strongly
leukopenic for over two weeks (data not shown). Six out of seven
naïve animals showed clinical lesions by day 3 post-cyclofosfamide
treatment and half of them died between day 6e8. The naïve
Fig. 8. AGMA1 reduces the burden of infection of HSV-2 genital infection in mice. Plots show the percent of animals that remained disease-free throughout the observation period.
A. Deﬁnition of timing of administration before infection. 6 animals/group were pretreated with AGMA1 at times indicated in the legend and then infected with 1 LD50 HSV-1.
Animals pretreated with AGMA1 15 s and 15 min before infection were fully protected or manifested milder clinical signs compared to naïve animals. B. Analysis of antiviral ef-
ﬁcacy against HSV-1 and HSV-2 infections. 6 animals/group were either untreated (Naïve) or pretreated with AGMA1 or carrier (Vehicle) 15 min before infection with 1 LD50 HSV-1
(top graph) or HSV-2 (lower). Asterisk indicates signiﬁcant differences relative to Naïve and Vehicle groups at p  0.05. C. Antiviral efﬁcacy against escalating infectious doses of
HSV-2. 10 animals/group were either untreated (Naïve) or pretreated with AGMA1 or carrier (Vehicle) 15 min before infection with 1 (top graph), 10 (middle), and 100 (lower) LD50.
Asterisk indicates signiﬁcant differences relative to Naïve and Vehicle groups at p  0.05.
Table 4
Analysis of viral reactivation in Naïve, Vehicle, and AGMA1-treated mice infected with 10 LD50 HSV-2 and, three months later, immunosuppressed with a bolus of
Cyclofosfamide.
Animal group Disease status at week 4 post-infection Disease status at week 4 post-immunosuppression
No. treated Dead Sicka Healthyb No. treated Dead Sick Healthy HSV-2 genome in nervous tissuesc
Naïve 11 4 6 1 7 3 3 1 3/2
Vehicle 11 6 5 0 5 3 2 0 0/0
AGMA1 11 3d 4 4 7 1 3 3 5/2
a Animals that were still sick at the end of follow-up or developed transient infection.
b Animals that remained disease-free throughout the follow-up.
c No. examined/no. positive animals for HSV-2 genome. Nested PCR analysis was performed in the sciatic nerve and cervical ganglia collected at week 4 post-
cyclophosphamide treatment.
d One death was likely unrelated to HSV infection as the animal died at day 3 post-infection and showed no clinical symptoms.
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no symptoms after immunosuppression, suggesting that this ani-
mal resisted infection. Clinical relapse also occurred in 5/5 Vehicle
animals, 3 of which died between day 8e11. In the AGMA1 group, 3/
7 mice that remained disease-free following infection also showed
no signs upon immunosuppression; 4/7 mice had clinical relapse
that was milder, delayed, and shorter compared to control animals.
Of note, three of themwere transiently infected and one showed no
signs of disease following primary infection (Table 4). At the end of
the experiment, animals were sacriﬁced, and their sciatic nerves
and cervical ganglia assayed for HSV-2 genome. All animals that
underwent clinical reactivation were PCR positive as opposed toanimals that were disease-free after immunosuppression and
tested negative (Table 4).4. Discussion
This study reports on the anti-herpetic activity of AGMA1, a
prevailingly cationic PAA that exerts antiviral activity with a mode
of action that differs from that of acyclovir. Indeed, immunoblotting
analysis revealed that AGMA1 blocks infection before the expres-
sion of immediate early viral genes, whereas acyclovir prevents late
viral genes expression. The antiviral activity of AGMA1 against
acyclovir-resistant strains supports this conclusion further. These
M. Donalisio et al. / Biomaterials 85 (2016) 40e53 51features prompted us to perform further studies in order to explore
the therapeutic potential of AGMA1 as an anti-herpetic compound.
Synthetic polycations have recently become the subject of much
interest as candidates for the prevention of viral infections. They
can inactivate the virus particle directly, as demonstrated for pol-
yethylenimine (PEI) against a panel of viruses, including HSV
[44,55e58], and for the poly(acrylic ester) Eudragit E100, hystidine
peptides, polylysine, and arginine, all of which are endowed with
membrane-destabilizing activity against HSV [59e62]. Although
AGMA1 shares a polycationic nature with the above mentioned
compounds, here we demonstrate that it does not inactivate the
virus particles. The lack of a direct effect of AGMA1 on the virus and
its capacity to inhibit the expression of immediate-early viral pro-
teins suggest that AGMA1 could act directly on target cells by
interfering with a very early event in HSV infection, possibly cor-
responding to virus attachment and/or entry. Indeed, our results
demonstrate that AGMA1 prevents HSV-1 and HSV-2 attachment.
Attachment assays showed that AGMA1 treatment prevents viral
particles from binding to the cell surface; this was further
demonstrated by immunoblotting the lysates from treated cells.
The initial interaction between HSV and the cell membrane is
mediated by interactions between the positively charged domains
on viral glycoproteins gC and gB and the negatively charged HSPGs
on the target cell membrane [63]. Others ﬁndings have revealed
that AGMA1 acts by binding to virus receptors on the surface of
target cells [36]. Of note, we have previously reported that AGMA1
exerts antiviral activity against other HSPG-dependent viruses [28].
Moreover, we have previously shown that, due to its polycationic
nature, AGMA1 is endowed with heparin-binding capacity and,
accordingly, tethers to HSPGs present on the surface of different
epithelial cell types, thereby masking these receptors and pre-
venting HPV attachment [36]. Indeed, the data reported in this
study demonstrate that AGMA1 binds to Vero cells in a HSPG-
dependent manner. However, they do not rule out other in-
teractions occurring between AGMA1 and the cell surface. To this
regard, it is important to point out that the side guanidine groups of
AGMA1 might reinforce membrane interactions, thanks to their
well-known chaotropic properties [28,36,64]. Interestingly are also
the observation that the binding of HSV-1 and 2 glycoproteins gD to
nectin-1 depends on several basic amino acids, including L25, R36,
R134 and R222 [65] and that HSV-2 infection can be mediated by
avb3 integrin [66] that is well known to bind its physiological or
pathological ligand via basic domains [67e69]. Taken together,
these data suggest that the high positive charge of AGMA1 may
mediate its binding to receptors different fromHSPGs, conferring to
the polymer a “multitarget” mechanism of action, as already
demonstrated for cationic dendrimer-like compounds [70].
An important feature of the AGMA1 antiviral activity that most
probably derives from its capacity to bind to and mask HSPGs, thus
preventing virus interaction, is its ability to diminish a cell's sus-
ceptibility to HSV when administered before virus infection. By
contrast, we show that heparin, a known attachment inhibitor that
interacts directly with the virus particle rather than with the cells,
did not show any inhibitory activity in the pre-treatment assay.
This feature prompted us to focus our studies on AGMA1 as a
potential microbicide for the prevention of the sexual transmission
of HSV infections.
The development of effective, safe, and topically applied
microbicides is an apt strategy to prevent STIs that cannot be
contained with pre-exposure immunization strategies or systemic
antiviral treatments.
The lack of a protective vaccine against HSV, the observation
that genital herpes increases susceptibility to HIV and other STIs
[8,71], and the inherent ability of herpesviruses to establish latent
infections underline the importance of topical microbicides toblock HSV mucosal transmission by inhibiting virus attachment
[72].
In recent years, numerous preclinical studies have been per-
formed mainly focused on negatively charged polyanions able to
bind to the viral envelope and block attachment, but none of these
compounds have passed phase III clinical trials [16,17]. Many den-
drimers have been screened for potential antiviral activity and
selected for development as candidate microbicides [18e20].
Beside the already mentioned cationic dendrimers whose main
mechanism of action is by binding and masking HSPGs to virus
attachment (see introduction), other compounds have been
developed among which the polyanionic sulfonated and carbox-
ylated polylysine dendrimers, shown to exhibit inhibitory activity
against HSV-1 and -2 infection in vitro and in vivo and protecting
animals against an intravaginal HSV-2 challenge [19].
Accordingly, SPL7013, a dendrimer with highly anionic charged
branches, has been developed by Starpharma Pty Ltd (Melbourne,
Australia) as microbicide against vaginal bacteriosis (marketed as
VivaGel) is currently under Phase 3 testing for its capacity to pre-
vent HIV and HSV infections [20,21].
Unlike these previous studies, we recommend a cationic PAA e
AGMA1e for further development as an active ingredient of topical
microbicides due to several important properties. First, AGMA1
shows antiviral activity in an organotypic model of cervicovaginal
epithelial tissue, i.e. the main target of HSV-2 infection. In this
system, a total inhibition of HSV, emerging from the apical surface,
was observed at different days post infection.
A second important property of AGMA1 is that, despite being
positively charged and in contrast with other polycationics (e.g.
PEI) it is not toxic, it is not hemolytic in the pH range 5.5e7.4 [22],
and it does not lead to an inﬂammatory response in the tissue
model. Third, when it was administered two hours pre-infection,
AGMA1 prevented infection in Epivaginal tissues, as observed
in vitro. Fourth, AGMA1 did not affect the growth of Lactobacillus
gasseri and Lactobacillus acidophilus, two components of the normal
vaginal ﬂora (data not shown). Fifth, AGMA1 antiviral activity was
not affected by acidic treatments (pH 3 and pH 5), that simulate
physiological vaginal environment.
Finally, it must be pointed out that severe HIV infection-driven
immunodeﬁciency causes a well documented increase in HSV as
well as HPV infection [73,74]. Conversely, HSV-2 infection clearly
enhances the transmission of HIV-1 infection [8]. Relevant to this
point, AGMA1 has been already demonstrated to prevent HPV
infection suggesting the possibility to obtain a formulation with a
multitarget mechanism of action that can control and/or prevent
multiple sexually transmitted infections simultaneously.
The in vitro results prompted us to test AGMA1 as a topical
microbicide against genital HSV infection in vivo. For this task we
used two virulent isolates shown to be difﬁcult to contain by
immunological means [38], a well-validated animal model, and a
clinical scoring largely used for HSV genital infection [47]. AGMA1
showed some antiviral efﬁcacy even when applied 30 min before
infection, a time lapse that compares favorably with other chemical
compounds for which antiviral activity has been shown to fade very
rapidly [75]. All in vivo tests were carried out by applying AGMA1
15 min before infection, which was performed with high input
loads of HSV-1 and HSV-2. AGMA1 signiﬁcantly reduced infection
rate and clinical grading even against 10 LD50 HSV-2, an infectious
dose that induced severe disease and high mortality rate in con-
trols. Finally, at 100 LD50, which killed 19/20 controls, AGMA1
reduced casualty to 4/10 animals and the 6 surviving animals
infection healed in three weeks. Since herpetic infections establish
life-long persistency in the host, a crucial matter is viral reac-
tivation upon appropriated stimuli. This was addressed in animals
that partially or apparently resisted initial infection. Here, animals
M. Donalisio et al. / Biomaterials 85 (2016) 40e5352were treated with a potent chemotherapeutic drug that reactivated
HSV-2 infection in 92% controls versus 57% AGMA1-treated ani-
mals. Further, clinical relapse in the latter group was milder and
transient suggesting that AGMA1 reduces the number of latently
infected cells and the potential for virus reactivation. In all, in vivo
tests indicate that AGMA1 provides signiﬁcant protection against
HSV infection and disease and compares favorably well with den-
drimers and polyanions considered good candidate topical micro-
bicides [18e21,34,58,75,76].
5. Future study
The main aim of this work was the evaluation of the activity and
toxicity of AGMA1. Considering the efﬁcacy and safety results ob-
tained, the next step of the research will concern the development
of an improved AGMA1 preparation intended for vaginal adminis-
tration as a microbicide. Formulation considerations and product
design will considered the regulatory aspects and will mainly
comprise the choice of excipients, the buffer capacity, the viscosity,
the stability and the shelf-life as well as the volume to be admin-
istered. The rheological properties and the vaginal distribution will
be also evaluated to obtain a desiderable microbicide product.
6. Conclusion
AGMA1 prevents HSV infection in vitro, ex vivo and in vivo and
shows a good biocompatibility proﬁle. Of consequence, AGMA1 is a
highly promising candidate for development as a topical microbi-
cide for the prevention of sexually transmitted HSV and HPV in-
fections. Further studies and the validation of the product in a
pharmaceutical formulation will be required to advance it for
clinical testing.
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